Palliative radiotherapy relieves symptoms of tumor-induced acute pancreatitis in two reported cases

Two patients with tumor-induced acute pancreatitis experienced pain relief and declining pancreatic enzymes after palliative radiotherapy of 8 Gy/2 or 20 Gy/5.

KEY POINTS

  • This Japanese case report describes two patients with tumor-induced acute pancreatitis (TIAP) resulting from malignant involvement of the pancreas. The first had extramedullary pancreatic involvement of multiple myeloma, while the second had pancreatic neuroendocrine carcinoma; both presented with abdominal pain, elevated pancreatic enzymes, and imaging abnormalities consistent with pancreatitis.
  • Case 1 involved a 59-year-old woman with progressive multiple myeloma after multiple systemic therapies and two autologous stem cell transplantations. At presentation, amylase was 489 U/L and lipase 1,273 U/L, with pancreatic head involvement and enlargement of the pancreatic tail. Following fasting, intravenous hydration, and antibiotics, the entire pancreas was irradiated to 8 Gy in two fractions using four-field 3D conformal RT.
  • In Case 1, epigastric pain improved four days after radiotherapy, and pancreatic enzymes continued to decline, reaching amylase 57 U/L and lipase 61 U/L ten days after irradiation. Enzyme levels had already begun decreasing with hydration before RT, so the independent treatment effect cannot be determined. No recurrence of pancreatitis was documented, but the patient died from progressive myeloma one month later.
  • Case 2 involved a 61-year-old man with pancreatic neuroendocrine carcinoma and extrapancreatic disease who developed pancreatitis approximately nine months after initiating chemotherapy. At presentation, amylase was 377 U/L and lipase 765 U/L, with enlarging intrapancreatic lesions. Palliative irradiation of the entire pancreas was delivered to 20 Gy in five fractions, alongside conservative management.
  • In Case 2, pancreatic enzyme concentrations decreased during treatment, reaching amylase 189 U/L and lipase 271 U/L by the final fraction, while abdominal pain improved three days after RT completion. Subsequent CT showed regression of pancreatic enlargement, and systemic therapy was continued following symptom improvement.
  • Neither patient experienced apparent acute radiation-related adverse events. However, the second patient developed recurrent abdominal pain and biochemical abnormalities with pancreatic lesion enlargement three months after irradiation, and died of progressive cancer four months after RT, demonstrating the limited durability of the observed response.
  • The authors also reviewed previously reported examples of RT for tumor-related pancreatitis, involving doses ranging from 20 Gy in 20 fractions to 50 Gy in 25 fractions, alongside other salvage regimens. The available evidence consists of isolated case reports with heterogeneous tumor types, supportive treatments, doses, and outcomes, leaving the optimal RT schedule and the specific contribution of irradiation undefined.

CLINICAL TAKEAWAY

Palliative radiotherapy may be considered as an individualized tumor-directed option for symptomatic tumor-induced pancreatitis when malignant pancreatic involvement is responsible and standard supportive measures are insufficient. These two cases illustrate possible pain relief and biochemical improvement using short-course RT, but they cannot establish treatment efficacy, optimal fractionation, or sustained symptom control.

SOURCE

Advances in Radiation Oncology

Browse more research Suggest a correction